Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gabapentin

M J McLean1

  • 1Department of Neurology, Department of Veterans Affairs Medical Center, Nashville, Tennessee, USA.

Epilepsia
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Gabapentin (GBP) is an amino acid antiepileptic drug effective for partial seizures. Its efficacy and safety profile, including minimal drug interactions and mild side effects, are detailed for clinical use.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Male quality, signal reliability and female choice: assessing the expectations of inter-sexual selection.

Journal of evolutionary biology·2012
Same author

A static magnetic field modulates severity of audiogenic seizures and anticonvulsant effects of phenytoin in DBA/2 mice.

Epilepsy research·2003
Same author

Two configurations of static magnetic fields for treating rheumatoid arthritis of the knee: a double-blind clinical trial.

Archives of physical medicine and rehabilitation·2001
Same author

Static magnetic field therapy for pain in the abdomen and genitals.

Pediatric neurology·2000
Same author

Efficacy of gabapentin as adjunctive therapy in a large, multicenter study. The Steps Study Group.

Seizure·2000
Same author

Effects of topiramate on sodium-dependent action-potential firing by mouse spinal cord neurons in cell culture.

Epilepsia·2000
Same journal

Factors associated with rapid pediatric acute seizure emergency treatment: Quality Improvement in Time to Treat Status Epilepticus baseline cohort.

Epilepsia·2026
Same journal

Outcome trajectories after pediatric epilepsy surgery vary by biopsychosocial phenotypes.

Epilepsia·2026
Same journal

Comparative risk of epilepsy with SGLT2 inhibitors versus incretin-based therapies in type 2 diabetes.

Epilepsia·2026
Same journal

Long-term mortality after status epilepticus: A 5-year analysis study.

Epilepsia·2026
Same journal

The Epilepsy-Cog study: Methods to establish a harmonized study of late onset epilepsy in a metacohort of six population-based cohorts in the United States.

Epilepsia·2026
Same journal

Systematic review and meta-analysis of lifestyle modification interventions and their impact on seizure reduction and quality of life.

Epilepsia·2026
See all related articles

Area of Science:

  • Pharmacology
  • Neuroscience
  • Clinical Pharmacy

Background:

  • Gabapentin (GBP) is an amino acid antiepileptic drug (AED) used for partial seizures in individuals over 12.
  • Its efficacy differs from standard AEDs in animal models, suggesting unique mechanisms of action.

Purpose of the Study:

  • To review the efficacy, mechanism of action, pharmacokinetics, and safety of gabapentin (GBP) for epilepsy treatment.
  • To summarize clinical data supporting GBP's use and identify areas for further research.

Main Methods:

  • Review of preclinical animal models and clinical trial data for FDA approval.
  • Analysis of pharmacokinetic properties, including absorption, metabolism, excretion, and drug interactions.
  • Compilation of safety data, including adverse events and pregnancy considerations.

Related Experiment Videos

Main Results:

  • Gabapentin (GBP) shows anticonvulsant effects potentially via GABA modulation and ion-channel actions.
  • Clinical response is dose-dependent, with efficacy not plateauing at tested doses.
  • GBP has minimal protein binding and liver metabolism, reducing drug-drug interactions. It is renally excreted, requiring dose adjustment based on creatinine clearance.
  • The drug is generally well-tolerated with mild to moderate CNS side effects. No severe systemic toxicity reported in 70,000 patients.
  • Gabapentin (GBP) is Category C due to rodent teratogenicity; human data is limited.

Conclusions:

  • Gabapentin (GBP) offers a distinct pharmacological profile for epilepsy management.
  • Further research, including monotherapy trials, is needed to fully define its clinical utility and safety.
  • Understanding its pharmacokinetics and tolerability is crucial for effective patient management.